SCYNEXIS Inc
NASDAQ:SCYX

Watchlist Manager
SCYNEXIS Inc Logo
SCYNEXIS Inc
NASDAQ:SCYX
Watchlist
Price: 0.6305 USD 0.1% Market Closed
Market Cap: 26.5m USD

Net Margin
SCYNEXIS Inc

-862.9%
Current
-645%
Average
4.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-862.9%
=
Net Income
-25.3m
/
Revenue
2.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
SCYNEXIS Inc
NASDAQ:SCYX
26.5m USD
-863%
US
Eli Lilly and Co
NYSE:LLY
999.6B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
501.2B USD
27%
CH
Roche Holding AG
SIX:ROG
256.7B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
210.6B GBP
16%
CH
Novartis AG
SIX:NOVN
206.2B CHF
26%
US
Merck & Co Inc
NYSE:MRK
250.5B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
209B USD
-126%
US
Pfizer Inc
NYSE:PFE
142.4B USD
16%
No Stocks Found

SCYNEXIS Inc
Glance View

Market Cap
26.5m USD
Industry
Pharmaceuticals

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 56 full-time employees. The company went IPO on 2014-05-02. The firm is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. The company has received the approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection). BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC). The company is also continuing late-stage clinical development of ibrexafungerp for multiple indications, including the treatment of life-threatening invasive fungal infections in hospitalized patients.

SCYX Intrinsic Value
0.2936 USD
Overvaluation 53%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-862.9%
=
Net Income
-25.3m
/
Revenue
2.9m
What is the Net Margin of SCYNEXIS Inc?

Based on SCYNEXIS Inc's most recent financial statements, the company has Net Margin of -862.9%.

Back to Top